Suppr超能文献

脂蛋白(a)与他汀类药物治疗的首次急性缺血性卒中患者的残余血管风险:一项前瞻性队列研究。

Lipoprotein(a) and residual vascular risk in statin-treated patients with first acute ischemic stroke: A prospective cohort study.

作者信息

Wang Lanjing, Liu Lijun, Zhao Yanhong, Chu Min, Teng Jijun

机构信息

Department of Neurology, The Affiliated Hospital of Qingdao University, Qingdao University, Qingdao, China.

Department of Neurology, Minhang Hospital, Fudan University, Qingdao, China.

出版信息

Front Neurol. 2022 Nov 3;13:1004264. doi: 10.3389/fneur.2022.1004264. eCollection 2022.

Abstract

OBJECTIVES

Statins either barely affect or increase lipoprotein(a) [Lp(a)] levels. This study aimed to explore the factors correlated to the change of Lp(a) levels as well as the relationship between Lp(a) and the recurrent vascular events in statin-treated patients with first acute ischemic stroke (AIS).

METHODS

Patients who were admitted to the hospital with first AIS from October 2018 to September 2020 were eligible for inclusion. Correlation between the change of Lp(a) levels and potential influencing factors was assessed by linear regression analysis. Cox proportional regression models were used to estimate the association between Lp(a) and recurrent vascular events including AIS, transient ischemic attack, myocardial infarction and coronary revascularization.

RESULTS

In total, 303 patients, 69.6% males with mean age 64.26 ± 11.38 years, completed the follow-up. During the follow-up period, Lp(a) levels increased in 50.5% of statin-treated patients and the mean percent change of Lp(a) levels were 14.48% (95% CI 6.35-22.61%). Creatinine (β = 0.152, 95% CI 0.125-0.791, = 0.007) and aspartate aminotransferase (AST) (β = 0.160, 95% CI 0.175-0.949, = 0.005) were positively associated with the percent change of Lp(a) levels. During a median follow-up of 26 months, 66 (21.8%) patients had a recurrent vascular event. The median time period between AIS onset and vascular events recurrence was 9.5 months (IQR 2.0-16.3 months). The on-statin Lp(a) level ≥70 mg/dL (HR 2.539, 95% CI 1.076-5.990, = 0.033) and the change of Lp(a) levels (HR 1.003, 95% CI 1.000-1.005, = 0.033) were associated with the recurrent vascular events in statin-treated patients with first AIS. Furthermore, the on-statin Lp(a) levels ≥70 mg/dL (HR 3.612, 95% CI 1.018-12.815, = 0.047) increased the risk of recurrent vascular events in patients with low-density lipoprotein cholesterol (LDL-C) levels < 1.8 mmol/L.

CONCLUSIONS

Lp(a) levels increased in half of statin-treated patients with first AIS. Creatinine and AST were positively associated with the percent change of Lp(a) levels. Lp(a) is a determinant of residual vascular risk and the change of Lp(a) is positively associated with the risk of recurrent vascular events in these patients.

摘要

目的

他汀类药物对脂蛋白(a)[Lp(a)]水平要么几乎没有影响,要么会使其升高。本研究旨在探讨与他汀类药物治疗的首次急性缺血性卒中(AIS)患者Lp(a)水平变化相关的因素,以及Lp(a)与复发性血管事件之间的关系。

方法

纳入2018年10月至2020年9月因首次AIS入院的患者。采用线性回归分析评估Lp(a)水平变化与潜在影响因素之间的相关性。采用Cox比例回归模型评估Lp(a)与复发性血管事件(包括AIS、短暂性脑缺血发作、心肌梗死和冠状动脉血运重建)之间的关联。

结果

共有303例患者完成随访,男性占69.6%,平均年龄64.26±11.38岁。在随访期间,50.5%的他汀类药物治疗患者Lp(a)水平升高,Lp(a)水平的平均变化百分比为14.48%(95%CI 6.35-22.61%)。肌酐(β = 0.152,95%CI 0.125-0.791,P = 0.007)和天冬氨酸转氨酶(AST)(β = 0.160,95%CI 0.175-0.949,P = 0.005)与Lp(a)水平变化百分比呈正相关。在中位随访26个月期间,66例(21.8%)患者发生复发性血管事件。AIS发病至血管事件复发的中位时间为9.5个月(IQR 2.0-16.3个月)。他汀治疗时Lp(a)水平≥70 mg/dL(HR 2.539,95%CI 1.076-5.990,P = 0.033)以及Lp(a)水平变化(HR 1.003,95%CI 1.000-1.005,P = 0.033)与他汀治疗的首次AIS患者复发性血管事件相关。此外,他汀治疗时Lp(a)水平≥70 mg/dL(HR 3.612,95%CI 1.018-12.815,P = 0.047)增加了低密度脂蛋白胆固醇(LDL-C)水平<1.8 mmol/L患者复发性血管事件的风险。

结论

他汀治疗的首次AIS患者中有一半Lp(a)水平升高。肌酐和AST与Lp(a)水平变化百分比呈正相关。Lp(a)是残余血管风险的一个决定因素,Lp(a)的变化与这些患者复发性血管事件的风险呈正相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c2a8/9671150/15e472451127/fneur-13-1004264-g0001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验